<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0"><akn:act><akn:meta><akn:identification source="#cosilico"><akn:FRBRWork prescriptive="true" authoritative="true"><akn:FRBRuri value="/akn/us/usc/42/1395w–115" /><akn:FRBRdate date="2025-12-31" name="retrieval" /><akn:FRBRauthor href="#us-congress" /><akn:FRBRcountry value="us" /></akn:FRBRWork><akn:FRBRExpression><akn:FRBRuri value="/akn/us/usc/42/1395w–115/eng@2025" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /><akn:FRBRlanguage language="en" /></akn:FRBRExpression><akn:FRBRManifestation><akn:FRBRuri value="/akn/us/usc/42/1395w–115/eng@2025/main.xml" /><akn:FRBRdate date="2025-12-31" /><akn:FRBRauthor href="#cosilico" /></akn:FRBRManifestation></akn:identification></akn:meta><akn:body><akn:section eId="sec_1395w_115"><akn:num>1395w–115</akn:num><akn:heading>Subsidies for part D eligible individuals for qualified prescription drug coverage</akn:heading><akn:content><akn:p>§ 1395w–115. Subsidies for part D eligible individuals for qualified prescription drug coverage(a) Subsidy paymentIn order to reduce premium levels applicable to qualified prescription drug coverage for part D eligible individuals consistent with an overall subsidy level of 74.5 percent (or, for each of 2024 through 2029, the percent applicable as a result of the application of section 1395w–113(a)(8) of this title, or, for 2030 and each subsequent year, 100 percent minus the percent specified under section 1395w–113(a)(9) of this title) for basic prescription drug coverage, to reduce adverse selection among prescription drug plans and MA–PD plans, and to promote the participation of PDP sponsors under this part and MA organizations under part C, the Secretary shall provide for payment to a PDP sponsor that offers a prescription drug plan and an MA organization that offers an MA–PD plan of the following subsidies in accordance with this section:(1) Direct subsidyA direct subsidy for each part D eligible individual enrolled in a prescription drug plan or MA–PD plan for a month equal to—(A) the amount of the plan’s standardized bid amount (as defined in section 1395w–113(a)(5) of this title), adjusted under subsection (c)(1), reduced by

(B) the base beneficiary premium (as computed under paragraph (2) or (8) of section 1395w–113(a) of this title (as applicable) and as adjusted under paragraph (1)(B) of such section).


(2) Subsidy through reinsuranceThe reinsurance payment amount (as defined in subsection (b)).



This section constitutes budget authority in advance of appropriations Acts and represents the obligation of the Secretary to provide for the payment of amounts provided under this section.

(b) Reinsurance payment amount(1) In generalThe reinsurance payment amount under this subsection for a part D eligible individual enrolled in a prescription drug plan or MA–PD plan for a coverage year is an amount equal to—(A) for a year preceding 2025, 80 percent of th</akn:p></akn:content><akn:subsection eId="subsec_1395w_115_a"><akn:num>(a)</akn:num><akn:heading>Subsidy payment</akn:heading><akn:content><akn:p>(a) Subsidy payment In order to reduce premium levels applicable to qualified prescription drug coverage for part D eligible individuals consistent with an overall subsidy level of 74.5 percent (or, for each of 2024 through 2029, the percent applicable as a result of the application of section 1395w–113(a)(8) of this title, or, for 2030 and each subsequent year, 100 percent minus the percent specified under section 1395w–113(a)(9) of this title) for basic prescription drug coverage, to reduce adverse selection among prescription drug plans and MA–PD plans, and to promote the participation of PDP sponsors under this part and MA organizations under part C, the Secretary shall provide for payment to a PDP sponsor that offers a prescription drug plan and an MA organization that offers an MA–PD plan of the following subsidies in accordance with this section: This section constitutes budget authority in advance of appropriations Acts and represents the obligation of the Secretary to provide </akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_115_b"><akn:num>(b)</akn:num><akn:heading>Reinsurance payment amount</akn:heading><akn:content><akn:p>(b) Reinsurance payment amount</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_115_c"><akn:num>(c)</akn:num><akn:heading>Adjustments relating to bids</akn:heading><akn:content><akn:p>(c) Adjustments relating to bids</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_115_d"><akn:num>(d)</akn:num><akn:heading>Payment methods</akn:heading><akn:content><akn:p>(d) Payment methods</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_115_e"><akn:num>(e)</akn:num><akn:heading>Portion of total payments to a sponsor or organization subject to risk (application of risk corridors)</akn:heading><akn:content><akn:p>(e) Portion of total payments to a sponsor or organization subject to risk (application of risk corridors)</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_115_f"><akn:num>(f)</akn:num><akn:heading>Disclosure of information</akn:heading><akn:content><akn:p>(f) Disclosure of information</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_115_g"><akn:num>(g)</akn:num><akn:heading>Payment for fallback prescription drug plans</akn:heading><akn:content><akn:p>(g) Payment for fallback prescription drug plans In lieu of the amounts otherwise payable under this section to a PDP sponsor offering a fallback prescription drug plan (as defined in section 1395w–111(g)(4) of this title 22 See References in Text note below.), the amount payable shall be the amounts determined under the contract for such plan pursuant to section 1395w–111(g)(5) of this title.</akn:p></akn:content></akn:subsection><akn:subsection eId="subsec_1395w_115_h"><akn:num>(h)</akn:num><akn:heading>Temporary retrospective subsidy for reduction in cost-sharing and deductible for adult vaccines recommended by the Advisory Committee on Immunization Practices and Insulin During 2023</akn:heading><akn:content><akn:p>(h) Temporary retrospective subsidy for reduction in cost-sharing and deductible for adult vaccines recommended by the Advisory Committee on Immunization Practices and Insulin During 2023</akn:p></akn:content></akn:subsection></akn:section></akn:body></akn:act></akn:akomaNtoso>